A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys

Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid and glucose metabolism. PPARgamma agonists improve insulin sensitivity and hyperglycemia and are effective in treating type 2 diabetes mellitus (T2DM), whereas PPARalpha agonists are used to treat dyslipidemi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pharmacology and experimental therapeutics 2010-06, Vol.333 (3), p.844-853
Hauptverfasser: Wagner, Janice D, Shadoan, Melanie K, Zhang, Li, Ward, Gina M, Royer, Lori J, Kavanagh, Kylie, Francone, Omar L, Auerbach, Bruce J, Harwood, Jr, H James
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 853
container_issue 3
container_start_page 844
container_title The Journal of pharmacology and experimental therapeutics
container_volume 333
creator Wagner, Janice D
Shadoan, Melanie K
Zhang, Li
Ward, Gina M
Royer, Lori J
Kavanagh, Kylie
Francone, Omar L
Auerbach, Bruce J
Harwood, Jr, H James
description Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid and glucose metabolism. PPARgamma agonists improve insulin sensitivity and hyperglycemia and are effective in treating type 2 diabetes mellitus (T2DM), whereas PPARalpha agonists are used to treat dyslipidemia and atherosclerosis. The goal here was to examine the efficacy of a selective PPARalpha agonist {(S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP-900691} on lipid, glycemic, and inflammation indices in 14 cynomolgus monkeys with spontaneous T2DM maintained on daily insulin therapy. Monkeys were dosed orally with either vehicle (n = 7) or CP-900691 (3 mg/kg, n = 7) daily for 6 weeks. CP-900691 treatment increased plasma high-density lipoprotein cholesterol (HDLC) (33 +/- 3 to 60 +/- 4 mg/dL, p < 0.001) and apolipoprotein A1 (96 +/- 5 to 157 +/- 5 mg/dL, p < 0.001), reduced plasma triglycerides (547 +/- 102 to 356 +/- 90 mg/dL, p < 0.01), and apolipoprotein B (62 +/- 3 to 45 +/- 3 mg/dL, p < 0.01), improved the lipoprotein index (HDL to non-HDLC ratio; 0.28 +/- 0.06 to 0.79 +/- 0.16, p < 0.001), decreased body weight (p < 0.01) and C-reactive protein (CRP) (1700 +/- 382 to 304 +/- 102 ng/ml, p < 0.01), and increased adiponectin (1697 +/- 542 to 4242 +/- 1070 ng/ml, p < 0.001) compared with baseline. CP-900691 treatment reduced exogenous insulin requirements by approximately 25% (p < 0.04) while lowering plasma fructosamine from 2.87 +/- 0.09 to 2.22 +/- 0.17 mM (p < 0.05), indicative of improved glycemic control. There were no changes in any of the aforementioned parameters in the vehicle group. Because low HDLC and high triglycerides are well established risk factors for cardiovascular disease, the marked improvements in these parameters, and in glycemic control, body weight, and CRP, suggest that CP-900691 may be of benefit in diabetic and obese or hyperlipidemic populations.
doi_str_mv 10.1124/jpet.110.166736
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733279802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733279802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c296t-e4afe69aab8913656eb267a42fce6ad26ecf095054833e75c5e1454922343c863</originalsourceid><addsrcrecordid>eNo9UU1P3DAQtapWZaE994Z862UD_s7miFYUKiHBAc7RrDPZGpw4tb2r7q_pX60DW07z3sybNyM9Qr5xdsG5UJfPE-aCCjOmluYDWXAteMU4kx_JgjEhKqmNPiGnKT0zxpUy8jM5EYw3M1uQv1c0oUeb3R7phDH8cSkMBcbgXY8RcogVzGPI2NGIFqfSouCnX0BhG0aX8pKuH6piaBq-pG4ou3tMdPKQBqDeTa5Ly7mGMsnoxsJg7OjWHywOzlIbxlzuUTfSzsEGc-kNYXzBQ_pCPvXgE3491jPy9OP6cX1b3d3f_Fxf3VVWNCZXqKBH0wBsVg2XRhvcCFODEr1FA50waHvWaKbVSkqstdXIlVaNEFJJuzLyjHx_8y0v_t5hyu3gkkXvYcSwS20tpaibFRNFefmmtDGkFLFvp-gGiIeWs3YOpZ1DKaiw11DKxvnRe7cZsHvX_09B_gMq84rI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733279802</pqid></control><display><type>article</type><title>A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Wagner, Janice D ; Shadoan, Melanie K ; Zhang, Li ; Ward, Gina M ; Royer, Lori J ; Kavanagh, Kylie ; Francone, Omar L ; Auerbach, Bruce J ; Harwood, Jr, H James</creator><creatorcontrib>Wagner, Janice D ; Shadoan, Melanie K ; Zhang, Li ; Ward, Gina M ; Royer, Lori J ; Kavanagh, Kylie ; Francone, Omar L ; Auerbach, Bruce J ; Harwood, Jr, H James</creatorcontrib><description><![CDATA[Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid and glucose metabolism. PPARgamma agonists improve insulin sensitivity and hyperglycemia and are effective in treating type 2 diabetes mellitus (T2DM), whereas PPARalpha agonists are used to treat dyslipidemia and atherosclerosis. The goal here was to examine the efficacy of a selective PPARalpha agonist {(S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP-900691} on lipid, glycemic, and inflammation indices in 14 cynomolgus monkeys with spontaneous T2DM maintained on daily insulin therapy. Monkeys were dosed orally with either vehicle (n = 7) or CP-900691 (3 mg/kg, n = 7) daily for 6 weeks. CP-900691 treatment increased plasma high-density lipoprotein cholesterol (HDLC) (33 +/- 3 to 60 +/- 4 mg/dL, p < 0.001) and apolipoprotein A1 (96 +/- 5 to 157 +/- 5 mg/dL, p < 0.001), reduced plasma triglycerides (547 +/- 102 to 356 +/- 90 mg/dL, p < 0.01), and apolipoprotein B (62 +/- 3 to 45 +/- 3 mg/dL, p < 0.01), improved the lipoprotein index (HDL to non-HDLC ratio; 0.28 +/- 0.06 to 0.79 +/- 0.16, p < 0.001), decreased body weight (p < 0.01) and C-reactive protein (CRP) (1700 +/- 382 to 304 +/- 102 ng/ml, p < 0.01), and increased adiponectin (1697 +/- 542 to 4242 +/- 1070 ng/ml, p < 0.001) compared with baseline. CP-900691 treatment reduced exogenous insulin requirements by approximately 25% (p < 0.04) while lowering plasma fructosamine from 2.87 +/- 0.09 to 2.22 +/- 0.17 mM (p < 0.05), indicative of improved glycemic control. There were no changes in any of the aforementioned parameters in the vehicle group. Because low HDLC and high triglycerides are well established risk factors for cardiovascular disease, the marked improvements in these parameters, and in glycemic control, body weight, and CRP, suggest that CP-900691 may be of benefit in diabetic and obese or hyperlipidemic populations.]]></description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.110.166736</identifier><identifier>PMID: 20190014</identifier><language>eng</language><publisher>United States</publisher><subject>Adiponectin - blood ; Animals ; Area Under Curve ; Blood Glucose - metabolism ; C-Reactive Protein - metabolism ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - genetics ; Dose-Response Relationship, Drug ; Glucose Tolerance Test ; Hypoglycemic Agents - pharmacology ; Hypolipidemic Agents ; Insulin Resistance ; Lipids - blood ; Lipoproteins - blood ; Macaca fascicularis ; Piperidines - pharmacology ; PPAR alpha - agonists ; Propionates - pharmacology ; Weight Loss - drug effects</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2010-06, Vol.333 (3), p.844-853</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c296t-e4afe69aab8913656eb267a42fce6ad26ecf095054833e75c5e1454922343c863</citedby><cites>FETCH-LOGICAL-c296t-e4afe69aab8913656eb267a42fce6ad26ecf095054833e75c5e1454922343c863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20190014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wagner, Janice D</creatorcontrib><creatorcontrib>Shadoan, Melanie K</creatorcontrib><creatorcontrib>Zhang, Li</creatorcontrib><creatorcontrib>Ward, Gina M</creatorcontrib><creatorcontrib>Royer, Lori J</creatorcontrib><creatorcontrib>Kavanagh, Kylie</creatorcontrib><creatorcontrib>Francone, Omar L</creatorcontrib><creatorcontrib>Auerbach, Bruce J</creatorcontrib><creatorcontrib>Harwood, Jr, H James</creatorcontrib><title>A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description><![CDATA[Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid and glucose metabolism. PPARgamma agonists improve insulin sensitivity and hyperglycemia and are effective in treating type 2 diabetes mellitus (T2DM), whereas PPARalpha agonists are used to treat dyslipidemia and atherosclerosis. The goal here was to examine the efficacy of a selective PPARalpha agonist {(S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP-900691} on lipid, glycemic, and inflammation indices in 14 cynomolgus monkeys with spontaneous T2DM maintained on daily insulin therapy. Monkeys were dosed orally with either vehicle (n = 7) or CP-900691 (3 mg/kg, n = 7) daily for 6 weeks. CP-900691 treatment increased plasma high-density lipoprotein cholesterol (HDLC) (33 +/- 3 to 60 +/- 4 mg/dL, p < 0.001) and apolipoprotein A1 (96 +/- 5 to 157 +/- 5 mg/dL, p < 0.001), reduced plasma triglycerides (547 +/- 102 to 356 +/- 90 mg/dL, p < 0.01), and apolipoprotein B (62 +/- 3 to 45 +/- 3 mg/dL, p < 0.01), improved the lipoprotein index (HDL to non-HDLC ratio; 0.28 +/- 0.06 to 0.79 +/- 0.16, p < 0.001), decreased body weight (p < 0.01) and C-reactive protein (CRP) (1700 +/- 382 to 304 +/- 102 ng/ml, p < 0.01), and increased adiponectin (1697 +/- 542 to 4242 +/- 1070 ng/ml, p < 0.001) compared with baseline. CP-900691 treatment reduced exogenous insulin requirements by approximately 25% (p < 0.04) while lowering plasma fructosamine from 2.87 +/- 0.09 to 2.22 +/- 0.17 mM (p < 0.05), indicative of improved glycemic control. There were no changes in any of the aforementioned parameters in the vehicle group. Because low HDLC and high triglycerides are well established risk factors for cardiovascular disease, the marked improvements in these parameters, and in glycemic control, body weight, and CRP, suggest that CP-900691 may be of benefit in diabetic and obese or hyperlipidemic populations.]]></description><subject>Adiponectin - blood</subject><subject>Animals</subject><subject>Area Under Curve</subject><subject>Blood Glucose - metabolism</subject><subject>C-Reactive Protein - metabolism</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Dose-Response Relationship, Drug</subject><subject>Glucose Tolerance Test</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypolipidemic Agents</subject><subject>Insulin Resistance</subject><subject>Lipids - blood</subject><subject>Lipoproteins - blood</subject><subject>Macaca fascicularis</subject><subject>Piperidines - pharmacology</subject><subject>PPAR alpha - agonists</subject><subject>Propionates - pharmacology</subject><subject>Weight Loss - drug effects</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UU1P3DAQtapWZaE994Z862UD_s7miFYUKiHBAc7RrDPZGpw4tb2r7q_pX60DW07z3sybNyM9Qr5xdsG5UJfPE-aCCjOmluYDWXAteMU4kx_JgjEhKqmNPiGnKT0zxpUy8jM5EYw3M1uQv1c0oUeb3R7phDH8cSkMBcbgXY8RcogVzGPI2NGIFqfSouCnX0BhG0aX8pKuH6piaBq-pG4ou3tMdPKQBqDeTa5Ly7mGMsnoxsJg7OjWHywOzlIbxlzuUTfSzsEGc-kNYXzBQ_pCPvXgE3491jPy9OP6cX1b3d3f_Fxf3VVWNCZXqKBH0wBsVg2XRhvcCFODEr1FA50waHvWaKbVSkqstdXIlVaNEFJJuzLyjHx_8y0v_t5hyu3gkkXvYcSwS20tpaibFRNFefmmtDGkFLFvp-gGiIeWs3YOpZ1DKaiw11DKxvnRe7cZsHvX_09B_gMq84rI</recordid><startdate>201006</startdate><enddate>201006</enddate><creator>Wagner, Janice D</creator><creator>Shadoan, Melanie K</creator><creator>Zhang, Li</creator><creator>Ward, Gina M</creator><creator>Royer, Lori J</creator><creator>Kavanagh, Kylie</creator><creator>Francone, Omar L</creator><creator>Auerbach, Bruce J</creator><creator>Harwood, Jr, H James</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201006</creationdate><title>A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys</title><author>Wagner, Janice D ; Shadoan, Melanie K ; Zhang, Li ; Ward, Gina M ; Royer, Lori J ; Kavanagh, Kylie ; Francone, Omar L ; Auerbach, Bruce J ; Harwood, Jr, H James</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c296t-e4afe69aab8913656eb267a42fce6ad26ecf095054833e75c5e1454922343c863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adiponectin - blood</topic><topic>Animals</topic><topic>Area Under Curve</topic><topic>Blood Glucose - metabolism</topic><topic>C-Reactive Protein - metabolism</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Dose-Response Relationship, Drug</topic><topic>Glucose Tolerance Test</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypolipidemic Agents</topic><topic>Insulin Resistance</topic><topic>Lipids - blood</topic><topic>Lipoproteins - blood</topic><topic>Macaca fascicularis</topic><topic>Piperidines - pharmacology</topic><topic>PPAR alpha - agonists</topic><topic>Propionates - pharmacology</topic><topic>Weight Loss - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wagner, Janice D</creatorcontrib><creatorcontrib>Shadoan, Melanie K</creatorcontrib><creatorcontrib>Zhang, Li</creatorcontrib><creatorcontrib>Ward, Gina M</creatorcontrib><creatorcontrib>Royer, Lori J</creatorcontrib><creatorcontrib>Kavanagh, Kylie</creatorcontrib><creatorcontrib>Francone, Omar L</creatorcontrib><creatorcontrib>Auerbach, Bruce J</creatorcontrib><creatorcontrib>Harwood, Jr, H James</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wagner, Janice D</au><au>Shadoan, Melanie K</au><au>Zhang, Li</au><au>Ward, Gina M</au><au>Royer, Lori J</au><au>Kavanagh, Kylie</au><au>Francone, Omar L</au><au>Auerbach, Bruce J</au><au>Harwood, Jr, H James</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2010-06</date><risdate>2010</risdate><volume>333</volume><issue>3</issue><spage>844</spage><epage>853</epage><pages>844-853</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract><![CDATA[Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid and glucose metabolism. PPARgamma agonists improve insulin sensitivity and hyperglycemia and are effective in treating type 2 diabetes mellitus (T2DM), whereas PPARalpha agonists are used to treat dyslipidemia and atherosclerosis. The goal here was to examine the efficacy of a selective PPARalpha agonist {(S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP-900691} on lipid, glycemic, and inflammation indices in 14 cynomolgus monkeys with spontaneous T2DM maintained on daily insulin therapy. Monkeys were dosed orally with either vehicle (n = 7) or CP-900691 (3 mg/kg, n = 7) daily for 6 weeks. CP-900691 treatment increased plasma high-density lipoprotein cholesterol (HDLC) (33 +/- 3 to 60 +/- 4 mg/dL, p < 0.001) and apolipoprotein A1 (96 +/- 5 to 157 +/- 5 mg/dL, p < 0.001), reduced plasma triglycerides (547 +/- 102 to 356 +/- 90 mg/dL, p < 0.01), and apolipoprotein B (62 +/- 3 to 45 +/- 3 mg/dL, p < 0.01), improved the lipoprotein index (HDL to non-HDLC ratio; 0.28 +/- 0.06 to 0.79 +/- 0.16, p < 0.001), decreased body weight (p < 0.01) and C-reactive protein (CRP) (1700 +/- 382 to 304 +/- 102 ng/ml, p < 0.01), and increased adiponectin (1697 +/- 542 to 4242 +/- 1070 ng/ml, p < 0.001) compared with baseline. CP-900691 treatment reduced exogenous insulin requirements by approximately 25% (p < 0.04) while lowering plasma fructosamine from 2.87 +/- 0.09 to 2.22 +/- 0.17 mM (p < 0.05), indicative of improved glycemic control. There were no changes in any of the aforementioned parameters in the vehicle group. Because low HDLC and high triglycerides are well established risk factors for cardiovascular disease, the marked improvements in these parameters, and in glycemic control, body weight, and CRP, suggest that CP-900691 may be of benefit in diabetic and obese or hyperlipidemic populations.]]></abstract><cop>United States</cop><pmid>20190014</pmid><doi>10.1124/jpet.110.166736</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2010-06, Vol.333 (3), p.844-853
issn 0022-3565
1521-0103
language eng
recordid cdi_proquest_miscellaneous_733279802
source MEDLINE; Alma/SFX Local Collection
subjects Adiponectin - blood
Animals
Area Under Curve
Blood Glucose - metabolism
C-Reactive Protein - metabolism
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - genetics
Dose-Response Relationship, Drug
Glucose Tolerance Test
Hypoglycemic Agents - pharmacology
Hypolipidemic Agents
Insulin Resistance
Lipids - blood
Lipoproteins - blood
Macaca fascicularis
Piperidines - pharmacology
PPAR alpha - agonists
Propionates - pharmacology
Weight Loss - drug effects
title A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T04%3A08%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20selective%20peroxisome%20proliferator-activated%20receptor%20alpha%20agonist,%20CP-900691,%20improves%20plasma%20lipids,%20lipoproteins,%20and%20glycemic%20control%20in%20diabetic%20monkeys&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Wagner,%20Janice%20D&rft.date=2010-06&rft.volume=333&rft.issue=3&rft.spage=844&rft.epage=853&rft.pages=844-853&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.110.166736&rft_dat=%3Cproquest_cross%3E733279802%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733279802&rft_id=info:pmid/20190014&rfr_iscdi=true